Search Results

Displaying Results 51-52 of 52 "'EMD'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight

Sep 10, 2025, 17:31 ET TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight

including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.